These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26453552)

  • 1. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
    Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
    Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model.
    Nasr RR; Hmadi RA; El-Eit RM; Iskandarani AN; Jabbour MN; Zaatari GS; Mahon FX; Pisano CC; Darwiche ND
    Int J Cancer; 2015 Aug; 137(3):698-709. PubMed ID: 25557649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism.
    Di Francesco AM; Meco D; Torella AR; Barone G; D'Incalci M; Pisano C; Carminati P; Riccardi R
    Biochem Pharmacol; 2007 Mar; 73(5):643-55. PubMed ID: 17150196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of the retinoid-related molecules (E)-3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) in F9 teratocarcinoma: Role of retinoic acid receptor gamma and retinoid-independent pathways.
    Parrella E; Giannì M; Fratelli M; Barzago MM; Raska I; Diomede L; Kurosaki M; Pisano C; Carminati P; Merlini L; Dallavalle S; Tavecchio M; Rochette-Egly C; Terao M; Garattini E
    Mol Pharmacol; 2006 Sep; 70(3):909-24. PubMed ID: 16788091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia/lymphoma.
    El Hajj H; Khalil B; Ghandour B; Nasr R; Shahine S; Ghantous A; Abdel-Samad R; Sinjab A; Hasegawa H; Jabbour M; Hall WW; Zaatari G; Dbaibo G; Pisano C; Bazarbachi A; Darwiche N
    Blood; 2014 Sep; 124(13):2072-80. PubMed ID: 25035162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models.
    Karam L; Houshaymi B; Abdel-Samad R; Jaafar M; Halloum I; Pisano C; Neipel F; Darwiche N; Abou Merhi R
    Oncol Rep; 2018 Feb; 39(2):721-730. PubMed ID: 29207182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synthetic retinoid ST1926 attenuates prostate cancer growth and potentially targets prostate cancer stem-like cells.
    Bahmad HF; Samman H; Monzer A; Hadadeh O; Cheaito K; Abdel-Samad R; Hayar B; Pisano C; Msheik H; Liu YN; Darwiche N; Abou-Kheir W
    Mol Carcinog; 2019 Jul; 58(7):1208-1220. PubMed ID: 30883933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.
    Zanchi C; Zuco V; Lanzi C; Supino R; Zunino F
    Cancer Res; 2005 Mar; 65(6):2364-72. PubMed ID: 15781651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activities of the synthetic retinoid ST1926 in two-dimensional and three-dimensional human breast cancer models.
    Aouad P; Saikali M; Abdel-Samad R; Fostok S; El-Houjeiri L; Pisano C; Talhouk R; Darwiche N
    Anticancer Drugs; 2017 Aug; 28(7):757-770. PubMed ID: 28471809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and pharmacological bases of the antitumor activity of a novel adamantyl retinoid, ST1926.
    Pisano C; Merlini L; Penco S; Carminati P; Zunino F
    J Chemother; 2004 Nov; 16 Suppl 4():74-6. PubMed ID: 15688616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response.
    Zuco V; Benedetti V; De Cesare M; Zunino F
    Int J Cancer; 2010 Mar; 126(5):1246-55. PubMed ID: 19676051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid.
    Zuco V; Zanchi C; Cassinelli G; Lanzi C; Supino R; Pisano C; Zanier R; Giordano V; Garattini E; Zunino F
    Cell Death Differ; 2004 Mar; 11(3):280-9. PubMed ID: 14657960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to the atypical retinoid ST1926 in SK-N-AS cells selected the subline rAS-ST with enhanced sensitivity to ATRA mediated by not conventional mechanisms: DNA damage, G2 accumulation and late telomerase inhibition.
    Di Francesco AM; Cusano G; Franzese O; Orienti I; Falconi M; Vesci L; Riccardi R
    Toxicol In Vitro; 2015 Oct; 29(7):1628-38. PubMed ID: 26096597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
    Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
    Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the molecular mechanisms underlying sensitivity/resistance to the atypical retinoid ST1926 in acute myeloid leukaemia cells: the role of histone H2A.Z, cAMP-dependent protein kinase A and the proteasome.
    Fratelli M; Fisher JN; Paroni G; Di Francesco AM; Pierri F; Pisano C; Godl K; Marx S; Tebbe A; Valli C; Gianni M; Stravalaci M; Gobbi M; Terao M; Garattini E
    Eur J Cancer; 2013 Apr; 49(6):1491-500. PubMed ID: 23245330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor Effect of the Atypical Retinoid ST1926 in Acute Myeloid Leukemia and Nanoparticle Formulation Prolongs Lifespan and Reduces Tumor Burden of Xenograft Mice.
    El-Houjeiri L; Saad W; Hayar B; Aouad P; Tawil N; Abdel-Samad R; Hleihel R; Hamie M; Mancinelli A; Pisano C; El Hajj H; Darwiche N
    Mol Cancer Ther; 2017 Oct; 16(10):2047-2057. PubMed ID: 28619754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel atypical retinoid endowed with proapoptotic and antitumor activity.
    Cincinelli R; Dallavalle S; Merlini L; Penco S; Pisano C; Carminati P; Giannini G; Vesci L; Gaetano C; Illy B; Zuco V; Supino R; Zunino F
    J Med Chem; 2003 Mar; 46(6):909-12. PubMed ID: 12620066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
    Barlow JW; Wiley JC; Mous M; Narendran A; Gee MF; Goldberg M; Sexsmith E; Malkin D
    Pediatr Blood Cancer; 2006 Nov; 47(6):773-84. PubMed ID: 16283617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of resistance to the atypical retinoid, ST1926, in the lung carcinoma cell line H460 is associated with reduced formation of DNA strand breaks and a defective DNA damage response.
    Zuco V; Zanchi C; Lanzi C; Beretta GL; Supino R; Pisano C; Barbarino M; Zanier R; Bucci F; Aulicino C; Carminati P; Zunino F
    Neoplasia; 2005 Jul; 7(7):667-77. PubMed ID: 16026646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.
    Al-Tahan A; Sarkis O; Harajly M; Baghdadi OK; Zibara K; Boulos F; Dighe D; Kregel S; Bazarbachi A; El-Sabban M; Skapek SX; Saab R
    Pediatr Blood Cancer; 2012 Jun; 58(6):877-84. PubMed ID: 21755593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.